Molecular Partners AG (MOLN) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, MOLN scores 50 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 12 / 20 (ROIC 0%; FCF yield 0%), Whale 13F Flow at 6 / 20 (institutional accumulation and options positioning), Insider Conviction at 9 / 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 10 / 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 13 / 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillars are Whale 13F Flow and Insider Conviction, which together signal limited institutional and insider endorsement. The Fundamental Cash Engine pillar reflects a reported 0% ROIC and 0% FCF yield, meaning the rating framework does not credit the company with current cash generation. The Forensic Balance Sheet pillar is the relative strength in the rating, with Altman Z 2.5 and Piotroski F 6/9 supporting a moderate balance-sheet assessment. The Macro Regime Fit pillar sits at a Beta of 1.0, meaning the source data characterizes the stock as moving in line with the broader market. Any upside case would depend on sentiment or catalyst-driven re-rating rather than on demonstrated cash earnings, while downside risk is framed by the rating's distribution warning.

Per the recent news and catalysts feed, the dominant headlines concern a workforce reduction, with reports stating up to 55 jobs may be cut, and later reports describing cuts of nearly half the workforce and up to 44%, alongside the company's pivot to radiopharmaceuticals. These items are tagged as catalysts and represent restructuring-related risk-watch items. A preclinical item reports that in mice a radioactive cancer candidate showed sustained tumor uptake relative to healthy tissues; this is tagged as market wire. A separate item reports that the MP0730 lead candidate was selected targeting CD70. One item reports H.C. Wainwright reiterated a Buy rating on the stock. Proprietary signals in the supply-chain graph: Not available in source data (the array is empty).

• What are the reported revenue, operating income, net income, and cash-flow figures for recent periods, given the financials section is empty?
• What is the current consensus rating and price target distribution, beyond the single H.C. Wainwright reiteration?
• What is the underlying holder composition behind the 6/20 Whale 13F and 9/20 Insider pillar scores?
• What is the scale and cash impact of the workforce reduction, and how does it affect the radiopharmaceutical pipeline timeline?
• What P/E, EV/EBITDA, and EPS figures apply, given they are marked unavailable while the RQD rating relies on zero-margin and zero-ROIC inputs?